Company intelligence / Profile preview

MiCo BioMed

Sungnam-si, Gyeonggi-do, South Koreamicobiomed-usa.com ↗

Ownership: Private
Employees: ~71
Development stage: Commercial

Overview

MiCo BioMed has commercialized multiple diagnostic platforms based on proprietary microfluidics and lab-on-a-chip technologies. Their Optimiser™ platform supports over 70 ELISA assays with proven enhancements in automation and throughput. The company’s molecular diagnostics products are used for rapid PCR testing—including COVID‑19—and a range of clinical chemistry applications.

Therapeutic areas: OtherMetabolic DisordersHematologyInfectious Diseases
Modalities: Lab-on-a-chip diagnosticsMolecular diagnostics devices (including PCR-based)Immunoassay platformsClinical chemistry analyzers
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on MiCo BioMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MiCo BioMed.

Explore the full profile